HSY 244
Alternative Names: HSY244Latest Information Update: 11 May 2023
At a glance
- Originator Novartis Pharmaceuticals
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atrial fibrillation
Most Recent Events
- 25 Apr 2023 Novartis Pharmaceuticals terminates phase-II clinical trial in Atrial fibrillation in Germany and US, due to business decision (IV) (EudraCT2020-004327-17) (NCT04582409)
- 30 Nov 2020 Phase-II clinical trials in Atrial fibrillation in Germany (IV) (EudraCT2020-004327-17) (NCT04582409)
- 30 Nov 2020 Phase-II clinical trials in Atrial fibrillation (In adults, In the elderly) in USA (IV) (NCT04582409)